IW-601
Behçet's disease (orphan inflammatory)
Phase 1b/2aPlanned
Key Facts
Indication
Behçet's disease (orphan inflammatory)
Phase
Phase 1b/2a
Status
Planned
About ImmuneWalk Therapeutics
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
View full company profileAbout ImmuneWalk Therapeutics
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
View full company profileAbout ImmuneWalk Therapeutics
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
View full company profileAbout ImmuneWalk Therapeutics
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
View full company profileAbout ImmuneWalk Therapeutics
ImmuneWalk pioneers adhesion‑checkpoint blockade to prevent immune‑cell infiltration in inflammatory disorders.
View full company profile